Abcellera Biologics Inc. · NASDAQ:ABCL

Abcellera Biologics — Q1 2022 Earnings Presentation

14 slides from Abcellera Biologics's earnings presentation, May 10, 2022

  1. Slide 1: AbCellera Q1 2022 Business Update

    Exhibit 99.2 Exhibit 99.2 AbCellera Q1 2022 BUSINESS UPDATE MAY 10, 2022 COPYRIGHT © ABCELLERA

  2. Slide 2: Disclaimer

    2 DISCLAIMER This presentation contains forward- looking statements including statement made pursuant to the safe harbor provisions of the private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management. All statements contained in this presentation other tha

  3. Slide 3: Strong Results & Focus on Key Priorities

    STRONG RESUTS & FOCUS ON KEY PRIORITIES 01 2022 BUSINESS UPDATE SUMMARY NEW programs under contract 6 NEW programs started 1 MOLECULE entered the clinic 158 cumulative programs under contract 84 cumulative programs started >$780M in cash, cash equivalents & marketable securities

  4. Slide 4: The best capabilities in the world from target to IND

    The best capabilities in the world from target to Ind Ind engine 2x faster solve the unsolvable Highest quality Unprecedented scale Composition of matter Patentable DNA sequence of the drug Drug substance GMP material for clinical testing Technology software+data science workforce infrastructure Tar

  5. Slide 5: Deal structures that capture downstream value

    Deal structures that capture downstream value we expanded our existing partnership with empirico to 7 targets, and the new agreement provides us with the option, on a program-by- program basis, to co-invest in preclinical and clinical development in exchange for a greater ownership stake in the prog

  6. Slide 6: A diverse panel of CD3 antibodies to create new cancer therapies

    A diverse panel of cd3 antibodies to create new cancer therapies we used our technology to find hundreds of cd3-binding antibodies that can be combine to create precision cancer therapies. We then used our clinically-validated bispecifics platform, orthomab tm to pair the cd3-binding antibodies with

  7. Slide 7: Q1 2022

    Q1 2022

  8. Slide 8: Strong portfolio growth

    Strong portfolio growth. Cumulative # of Program Starts Cumulative # of Molecules in the clicnic Total # of Programs Under Contract 158 Total # of Discovery Partners 36 84 90 80 70 60 50 40 30 20 10 0 84 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 6 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q

  9. Slide 9: Molecules in the clinic and authorized for emergency use

    9 Q12022 BUSINESS UPDATE 6 molecule in the clinic,2 authorized for emergency use. MOLECULE STAGE PARTNER THERAPEUTIC AREA PROGRAM TYPE bamanivimab (LY Cov555) Marketed Emergency Use Authorization (EUA) lilly infectious disease Covid 19 Abcellera Discovery partnership bebtelovimab (LY-CoV1404) Market

  10. Slide 10: $316.5M total revenue, driven by royalties

    $316.5M total revenue, driven by royalties for bamlanivimab and bebtelovimab. Revenue USD 316.5M ROYALTIES MILESTONES LICENSING RESEARCH FEES $202.8M $171.5M $7.0M $4.0M $20.3M Q1 2021 $307.0M $9.3M $0.2M Q1 2021 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE 10

  11. Slide 11: Operating expenses reflect strengthening of the platform

    Q1 2022 BUSINESS UPDATE Operating expenses reflect strengthening of the platform. Operating Expenses USD RESEARCH & DEVELOPMENT +$14.0M $12.4M Q1 2021 $26.4M Q1 2022 SALES & MARKETING -$0.2M $2.5M Q1 2021 $2.4M Q1 2022 GENERAL & ADMIN +$7.8M $6.5M Q1 2021 $14.3M Q1 2022 11 COPYRIGHT © ABCELLERA FINA

  12. Slide 12: Net earnings of $168.6M

    12 COPYRIGHT © ABCELLERA Q1 2022 BUSINESS UPDATE FINANCIALS Net earning of $168.6M: equivalent to 0.59 (basic) and 0.54 (diluted) per share. Earning USD NET EARNINGS EARNING PER SHARE: BASIC EARNING PER SHARE: DILUTED $117.1M Q1 2021 $168.6M Q1 2022 $0.43 2021 Q1 $0.59 2022 Q1 $0.37 2021 Q1 $0.54 20

  13. Slide 13: Over $780 million in total cash, equivalents, and marketable securities

    Over $780 million in total cash, equivalents, and marketable securities Cash Flows USD Q1 2022 BUSINESS UPDATE $748M $247M $476M $25M $100M [$26M] [$3M] $0M $812M $240M Marketable $547M Cash&Equivalents $25M Restricted Cash 23-Dec-21 OPERATING INVESTING FINANCING FX 31-MAR-22 13 COPYRIGHT © ABCELLER

  14. Slide 14: Thank You

    Q1 2022 BUSINESS UDPATE COPYRIGHT © ABCELLERA 14 THANK YOU

AbCellera Biologics — Q1 2022 Earnings Presentation on 6ix